CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
CCTG HNC2 (NRG HN004) - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin Has now been centrally activated in Canada, the trial is being led by NRG Oncology in the US, and CCTG is sponsor in Canada.
Did you know that we have some amazing music talent hiding in ranks of CCTG? There has been a friendly (?) music rivalry between Dr. Jim Biagi (Old DOCS New Tricks) and Dr. Dan Renouf (Desolation Sound Machine) and they are letting everyone at the CCTG Spring Meeting be entertained and be the judges of who has the best band.
Every year at the CCTG Spring Meeting we recognize individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group. Presentation of the awards will happen at the Recognition Awards Ceremony on Friday May 3 from 5:30 to 6:00 at the Chelsea Hotel in Toronto. We are honored to acknowledge the 2019 CCTG Recognition Awards winners.
Updated results of the CCTG MAC.7 | SWOG 0226 study have recently been published in the New England Journal of Medicine. Long-term results of a phase III trial showed that women with metastatic hormone-sensitive breast cancer lived nearly 8 months longer with the addition of fulvestrant (Faslodex) to first-line anastrozole (Arimidex).
ALC.6 (A041501), A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL, has been centrally activated.
About the trial
All participants at our member sites will be required to attest to the completion of this one-time training requirement by April 30, 2019.
